<DOC>
	<DOC>NCT00228605</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.</brief_summary>
	<brief_title>Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Chronic pain diagnosis Opioid tolerant Has on average 14 breakthrough pain episodes per day Drug abuse history Cardiopulmonary disease Monoamine oxidase inhibitors (MAOIs) Expected to have surgery to relieve the pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Pain</keyword>
	<keyword>Sudden Pain</keyword>
	<keyword>Flares</keyword>
	<keyword>noncancer</keyword>
	<keyword>low back pain</keyword>
	<keyword>neuropathic pain</keyword>
	<keyword>osteoarthritis pain</keyword>
	<keyword>migraine</keyword>
	<keyword>chronic headache</keyword>
	<keyword>diabetic peripheral neuropathy</keyword>
</DOC>